S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

$4.56
+0.06 (+1.33%)
(As of 04:00 PM ET)
Compare
Today's Range
$4.36
$4.57
50-Day Range
$4.44
$7.67
52-Week Range
$4.36
$10.41
Volume
4.08 million shs
Average Volume
5.22 million shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.54

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
331.3% Upside
$19.54 Price Target
Short Interest
Bearish
15.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.93mentions of Iovance Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$26.56 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

88th out of 975 stocks

Biological Products, Except Diagnostic Industry

9th out of 162 stocks


IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Price History

IOVA Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Update
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Check Out What Whales Are Doing With IOVA
Why Shares of Iovance Biotherapeutics Dropped Thursday
Iovance down 13% as downward trend continues
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
503
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.54
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+340.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$-395,890,000.00
Pretax Margin
-176,181.52%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.66 per share

Miscellaneous

Free Float
222,008,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.10

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 49)
    J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 50)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 50)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 56)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    VP of Investor Relations & PR
  • Ms. Tracy Winton
    Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A. (Age 63)
    Chief Bus. Officer
  • Mr. James Ziegler M.B.A.
    Exec. VP of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Sr. VP & Head of Digital and Information Technology













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

13 Wall Street analysts have issued twelve-month price targets for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's share price to reach $19.54 in the next twelve months. This suggests a possible upside of 340.1% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the start of the year. Since then, IOVA shares have decreased by 30.5% and is now trading at $4.44.
View the best growth stocks for 2023 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.34. The biotechnology company had revenue of $0.24 million for the quarter, compared to analyst estimates of $3.91 million. During the same period in the previous year, the firm earned ($0.63) earnings per share.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.86%), Perceptive Advisors LLC (5.66%), State Street Corp (5.47%), Point72 Asset Management L.P. (3.14%), Artisan Partners Limited Partnership (1.79%) and Geode Capital Management LLC (1.67%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $4.44.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.10 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 503 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -